| 1 |
23961253 | Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer. | 2013 Jan |
1 |
| 2 |
22249974 | Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. | 2012 Jun |
5 |
| 3 |
19771426 | (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. | 2010 Feb |
1 |
| 4 |
20610158 | Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. | 2010 Jul |
1 |
| 5 |
20964447 | HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. | 2010 Nov 17 |
1 |
| 6 |
18594815 | Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. | 2008 Dec |
2 |
| 7 |
17565496 | 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. | 2007 Nov |
2 |